Author: Gulli Arnason

  • Arctic Therapeutics research suggests preventative strategy against HCCAA

    Arctic Therapeutics research suggests preventative strategy against HCCAA

    —

    By

    Gulli Arnason

    Icelandic drug discovery and development company Arctic Therapeutics (ATx) today announced the publication of research in JAMA Neurology, which informs a possible therapeutic strategy to treat a rare form of familial dementia. N-acetylcysteine (NAC) shows promise to treat hereditary cystatin C amyloid angiopathy (HCCAA) HCCAA – a subtype of cerebral amyloid angiopathy (CAA) – is…